<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00367562</url>
  </required_header>
  <id_info>
    <org_study_id>TEREKOWA33</org_study_id>
    <nct_id>NCT00367562</nct_id>
  </id_info>
  <brief_title>Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy</brief_title>
  <official_title>Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Britanico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Britanico</source>
  <brief_summary>
    <textblock>
      TO ASSESS THE EFFICACY OF THE RENIN ANGIOTENSIN SYSTEM PLUS STEROIDS TO DECREASE THE AMOUNT
      OF PROTEINURIA IN IGA NEPHROPATHY
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients whose proteinuria was &gt; 0.5 g/day were to receive enalapril plus valsartan coupled
      with oral 0.5 g/day of methylprednisone for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1996</start_date>
  <completion_date>December 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DAILY PROTEINURIA</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>RENAL FUNCTION AS ASSESSED BY SERUM CREATININE</measure>
  </secondary_outcome>
  <enrollment>20</enrollment>
  <condition>IGA Nephropathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ENALAPRIL VALSARTAN METHYLPREDNISONE</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PATIENTES WITH IGA NEPHROPATHY WITH PROTEINURIA OVER 0.5 G/DAY

        Exclusion Criteria:

          -  MALIGNANCY, RENAL FAILURE
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hernan trimarchi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Britanico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Britanico de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1280</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <link>
    <url>http://www.asn-online.org</url>
  </link>
  <reference>
    <citation>Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol. 2005 Jul;16(7):2088-97. Epub 2005 Jun 1. Review.</citation>
    <PMID>15930092</PMID>
  </reference>
  <reference>
    <citation>Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, Kim MJ. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin Nephrol. 2003 Nov;60(5):318-26.</citation>
    <PMID>14640237</PMID>
  </reference>
  <reference>
    <citation>Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, Minutolo R. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis. 1999 May;33(5):851-6.</citation>
    <PMID>10213639</PMID>
  </reference>
  <reference>
    <citation>Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001 Jul;38(1):18-25.</citation>
    <PMID>11431176</PMID>
  </reference>
  <reference>
    <citation>Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int. 2006 Jun;69(11):1939-44. Review.</citation>
    <PMID>16641925</PMID>
  </reference>
  <reference>
    <citation>Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, Ito K, Iitaka K, Koitabashi Y, Yamaoka K, Nakagawa K, Nakamura H, Matsuyama S, Seino Y, Takeda N, Hattori S, Ninomiya M. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol. 1999 Jan;10(1):101-9.</citation>
    <PMID>9890315</PMID>
  </reference>
  <reference>
    <citation>Kobayashi Y, Hiki Y, Fujii K, Kurokawa A, Tateno S. Moderately proteinuric IgA nephropathy: prognostic prediction of individual clinical courses and steroid therapy in progressive cases. Nephron. 1989;53(3):250-6.</citation>
    <PMID>2797345</PMID>
  </reference>
  <reference>
    <citation>Katafuchi R, Ikeda K, Mizumasa T, Tanaka H, Ando T, Yanase T, Masutani K, Kubo M, Fujimi S. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis. 2003 May;41(5):972-83.</citation>
    <PMID>12722031</PMID>
  </reference>
  <reference>
    <citation>Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999 Mar 13;353(9156):883-7.</citation>
    <PMID>10093981</PMID>
  </reference>
  <reference>
    <citation>Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA. Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrology (Carlton). 2004 Aug;9(4):177-85.</citation>
    <PMID>15363047</PMID>
  </reference>
  <verification_date>January 1996</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2006</study_first_submitted>
  <study_first_submitted_qc>August 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2006</study_first_posted>
  <last_update_submitted>October 31, 2006</last_update_submitted>
  <last_update_submitted_qc>October 31, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2006</last_update_posted>
  <keyword>IGA NEPHROPATHY</keyword>
  <keyword>STEROIDS</keyword>
  <keyword>ENALAPRIL</keyword>
  <keyword>VALSARTAN</keyword>
  <keyword>PROTEINURIA</keyword>
  <keyword>IMMUNOGLOBULIN A NEPHROPATHY (IGA NEPHROPATHY)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

